Log In
Print
BCIQ
Print
Print this Print this
 

INO-8000, VGX-6150

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionSynCon DNA vaccine covering HCV genotype 1
Molecular Target HCV NS3/4A protease complex ; HCV NS4B transmembrane protein
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotypes 1a and 1b infection
Regulatory Designation

Partner

VGX International Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today